What are the stages of chronic kidney disease? Here's what you need to know about the symptoms and slowing progression.

FDA staff raised familiar safety concerns about sotagliflozin as a treatment for type 1 diabetes (T1D) as the agency again ...

The FDA rejected sotagliflozin 5 years ago for the same indication but for the broader population of adults with T1D, due to ...

Greater protein intake in chronic kidney disease may lower mortality, and clinicians should routinely evaluate food intake with attention to energy and protein. Older people with mild to moderate ...

Lacosamide: no dose adjustment is considered necessary in patients with mild or moderate renal impairment. A maximum dose of 300 mg/day should not be exceeded in patients with severe renal ...

The FDA panel voted against the approval of sotagliflozin for patients with type 1 diabetes and chronic kidney disease.

Objectives: To determine if baseline renal function affects the efficacy and safety of romosozumab. Results: At baseline, most patients had mild/moderate renal insufficiency: 84% in ARCH, 88% in FRAME ...